339 related articles for article (PubMed ID: 9872321)
41. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.
Shen HW; Gao SL; Wu YL; Peng SY
World J Gastroenterol; 2005 Oct; 11(38):5926-30. PubMed ID: 16273601
[TBL] [Abstract][Full Text] [Related]
42. Expression of death decoy receptor-3 (DcR3) in human breast cancer and its functional effects on breast cancer cells in vitro.
Ge Z; Sanders AJ; Ye L; Wang Y; Jiang WG
J Exp Ther Oncol; 2011; 9(2):109-18. PubMed ID: 21699018
[TBL] [Abstract][Full Text] [Related]
43. Amplification and expression of a decoy receptor for fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas.
Ohshima K; Haraoka S; Sugihara M; Suzumiya J; Kawasaki C; Kanda M; Kikuchi M
Cancer Lett; 2000 Nov; 160(1):89-97. PubMed ID: 11098089
[TBL] [Abstract][Full Text] [Related]
44. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis.
Yu KY; Kwon B; Ni J; Zhai Y; Ebner R; Kwon BS
J Biol Chem; 1999 May; 274(20):13733-6. PubMed ID: 10318773
[TBL] [Abstract][Full Text] [Related]
45. The CD95 system and the death of a lymphocyte.
Matiba B; Mariani SM; Krammer PH
Semin Immunol; 1997 Feb; 9(1):59-68. PubMed ID: 9106308
[TBL] [Abstract][Full Text] [Related]
46. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer.
Lin WW; Hsieh SL
Biochem Pharmacol; 2011 Apr; 81(7):838-47. PubMed ID: 21295012
[TBL] [Abstract][Full Text] [Related]
47. Malignant lymphoma arising from natural killer cells: report of the first case in 1970 and newer developments in the FasL-->FasR system.
Sinkovics JG
Acta Microbiol Immunol Hung; 1997; 44(3):295-303. PubMed ID: 9468734
[TBL] [Abstract][Full Text] [Related]
48. Modulation of dendritic cell differentiation and maturation by decoy receptor 3.
Hsu TL; Chang YC; Chen SJ; Liu YJ; Chiu AW; Chio CC; Chen L; Hsieh SL
J Immunol; 2002 May; 168(10):4846-53. PubMed ID: 11994433
[TBL] [Abstract][Full Text] [Related]
49. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster.
Bai C; Connolly B; Metzker ML; Hilliard CA; Liu X; Sandig V; Soderman A; Galloway SM; Liu Q; Austin CP; Caskey CT
Proc Natl Acad Sci U S A; 2000 Feb; 97(3):1230-5. PubMed ID: 10655513
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics, metabolic stability, and subcutaneous bioavailability of a genetically engineered analog of DcR3, FLINT [DcR3(R218Q)], in cynomolgus monkeys and mice.
Wroblewski VJ; McCloud C; Davis K; Manetta J; Micanovic R; Witcher DR
Drug Metab Dispos; 2003 Apr; 31(4):502-7. PubMed ID: 12642478
[TBL] [Abstract][Full Text] [Related]
51. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells.
Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031
[TBL] [Abstract][Full Text] [Related]
52. Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells.
Asanuma K; Tsuji N; Endoh T; Yagihashi A; Watanabe N
J Immunol; 2004 Mar; 172(6):3922-9. PubMed ID: 15004200
[TBL] [Abstract][Full Text] [Related]
53. Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.
Liu W; Ramagopal U; Cheng H; Bonanno JB; Toro R; Bhosle R; Zhan C; Almo SC
Structure; 2016 Nov; 24(11):2016-2023. PubMed ID: 27806260
[TBL] [Abstract][Full Text] [Related]
54. Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells.
Xu T; Sun BC; Li Q; Hao XS
World J Gastroenterol; 2005 Jul; 11(25):3915-9. PubMed ID: 15991293
[TBL] [Abstract][Full Text] [Related]
55. Over-expression of the decoy receptor 3 (DcR3) gene in peripheral blood mononuclear cells (PBMC) derived from silicosis patients.
Otsuki T; Tomokuni A; Sakaguchi H; Aikoh T; Matsuki T; Isozaki Y; Hyodoh F; Ueki H; Kusaka M; Kita S; Ueki A
Clin Exp Immunol; 2000 Feb; 119(2):323-7. PubMed ID: 10632670
[TBL] [Abstract][Full Text] [Related]
56. Idiopathic pulmonary fibrosis fibroblasts become resistant to Fas ligand-dependent apoptosis via the alteration of decoy receptor 3.
Im J; Kim K; Hergert P; Nho RS
J Pathol; 2016 Sep; 240(1):25-37. PubMed ID: 27218286
[TBL] [Abstract][Full Text] [Related]
57. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis.
Roth W; Isenmann S; Nakamura M; Platten M; Wick W; Kleihues P; Bähr M; Ohgaki H; Ashkenazi A; Weller M
Cancer Res; 2001 Mar; 61(6):2759-65. PubMed ID: 11289159
[TBL] [Abstract][Full Text] [Related]
58. Retinoic acid morpholine amide (RAMA) inhibits expression of Fas ligand through EP1 receptor in colon cancer cells.
Chen SX; Du SY; Wang YT; Zhao HC; Zhang YL; Yao L
Tumour Biol; 2016 Jan; 37(1):323-9. PubMed ID: 26211005
[TBL] [Abstract][Full Text] [Related]
59. Attenuation of Th1 response in decoy receptor 3 transgenic mice.
Hsu TL; Wu YY; Chang YC; Yang CY; Lai MZ; Su WB; Hsieh SL
J Immunol; 2005 Oct; 175(8):5135-45. PubMed ID: 16210617
[TBL] [Abstract][Full Text] [Related]
60. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.
Yamana K; Bilim V; Hara N; Kasahara T; Itoi T; Maruyama R; Nishiyama T; Takahashi K; Tomita Y
Br J Cancer; 2005 Sep; 93(5):544-51. PubMed ID: 16091761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
